<code id='D2313C5CA5'></code><style id='D2313C5CA5'></style>
    • <acronym id='D2313C5CA5'></acronym>
      <center id='D2313C5CA5'><center id='D2313C5CA5'><tfoot id='D2313C5CA5'></tfoot></center><abbr id='D2313C5CA5'><dir id='D2313C5CA5'><tfoot id='D2313C5CA5'></tfoot><noframes id='D2313C5CA5'>

    • <optgroup id='D2313C5CA5'><strike id='D2313C5CA5'><sup id='D2313C5CA5'></sup></strike><code id='D2313C5CA5'></code></optgroup>
        1. <b id='D2313C5CA5'><label id='D2313C5CA5'><select id='D2313C5CA5'><dt id='D2313C5CA5'><span id='D2313C5CA5'></span></dt></select></label></b><u id='D2313C5CA5'></u>
          <i id='D2313C5CA5'><strike id='D2313C5CA5'><tt id='D2313C5CA5'><pre id='D2313C5CA5'></pre></tt></strike></i>

          
          WSS
          Illustration of two DNA strands made of banknotes. -- health coverage from STAT
          Adobe

          The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge a few times a year to scold drugmakers for pricing their latest cancer or MS advance far beyond reason.

          But last year, they sat down and concluded a forthcoming treatment was worth up to $3.9 million — more than any medicine in history, more than a 45-year supply of Humira, the autoimmune drug often held up as an emblem of America’s runaway drug spending. 

          advertisement

          It was a testament to the power of a new class of gene therapies to deliver something pharma so rarely does: Genuine cures. The treatment, approved last week as Lenmeldy, may allow some babies born with an ultra-rare neurodegenerative disease called metachromatic leukodystrophy, or MLD, to grow up and live essentially normal lives.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia